Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus Docetaxel in Advanced NSCLC
NCT03411967Phase 2Unknown
- Sponsor
- Zigong First People's Hospital
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Zigong First People's Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03411967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411967.